New Stock News | Pukui Pharmaceutical Hong Kong Stock IPO Prospectus Invalid

06:56 21/07/2026

Beijing Puqi Pharmaceutical Technology Co., Ltd. (referred to as "Puqi Medicine") submitted its Hong Kong IPO prospectus on January 21, 2026, which expired after 6 months on July 21, 2026. CITIC Securities and Minsheng Capital act as joint sponsors.

Beijing Puqi Pharmaceutical Technology Co., Ltd. (referred to as Puqi Medicine) submitted its Hong Kong stock prospectus on January 21, 2026, which expired after 6 months on July 21, 2026. CITIC SEC and CMBC CAPITAL are the joint sponsors. The prospectus shows that Puqi Medicine is a biotechnology company focusing on the field of immune inflammation, dedicated to becoming a leader in targeted therapy delivery. Since its establishment in 2016, the company has focused on the treatment of chronic inflammatory diseases with innovative original designs and precise local delivery as its core capabilities, aiming to provide innovative solutions that combine efficacy, safety, and long-term patient satisfaction.

Shandong Yabo Technology's subsidiary wins bid for 99.8 million yuan related energy storage power station project.

Subsidiary of Long Yuan Construction Group (600491.SH) wins bid for 556 million yuan project in the Yangtze River Delta Automobile Innovation Park.

HK Stock Market Move | PATEO (02889) rose more than 12% at the end of the session, making the company a member of the Application Working Group of the Ministry of Industry and Information Technology's Siasun Robot & Automation and Embodied Intelligence Standards Committee.

Shandong Yabo Technology's subsidiary wins bid for 99.8 million yuan related energy storage power station project.

Subsidiary of Long Yuan Construction Group (600491.SH) wins bid for 556 million yuan project in the Yangtze River Delta Automobile Innovation Park.